Cancer Discov. 2013 Jul;3(7):OF1. doi: 10.1158/2159-8290.CD-NB2013-088. Epub 2013 Jun 13.
The U.S. Food and Drug Administration approved radium-223 dichloride for treatment of men with metastatic castration-resistant prostate cancer that has spread to the bone.
美国食品和药物管理局批准镭-223 二氯化物用于治疗转移性去势抵抗性前列腺癌已扩散到骨骼的男性。